Literature DB >> 11146451

Orally administered bovine lactoferrin systemically inhibits VEGF(165)-mediated angiogenesis in the rat.

K Norrby1, I Mattsby-Baltzer, M Innocenti, S Tuneberg.   

Abstract

Lactoferrin (Lf) systemically suppresses tumor growth and metastasis by unknown mechanisms. We have studied the effect of orally administered iron-unsaturated bovine Lf on angiogenesis induced by VEGF(165) and IL-1-alpha in adult rats using the mesenteric-window angiogenesis assay. VEGF(165) is a major angiogenic factor in most, if not all, tumors and other angiogenesis diseases of clinical relevance. A number of objective angiogenesis variables were analyzed using microscopic morphometry and image analysis. Lf treatment significantly inhibited the VEGF(165)-mediated response in terms of microvessel spatial extension, overall vascularity and incidence of crossover. The response to IL-1-alpha decreased significantly only in terms of microvessel crossover. In vitro, Lf exerted an antiproliferative effect on endothelial cells. To our knowledge, Lf is the first endogenous protein that has been shown to be antiangiogenic following oral administration. The oral administration of Lf thus appears to be of potential interest as an antiangiogenesis treatment modality in the clinical setting. Since tumor growth is angiogenesis dependent, the extensive therapeutic potential warrants further study to elucidate the mechanisms responsible for the angiostatic effect of Lf. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11146451     DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1024>3.3.co;2-k

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Lactoferrin inhibits the inflammatory and angiogenic activation of bovine aortic endothelial cells.

Authors:  Mijung Yeom; Jongbong Park; Bombi Lee; Sang-Yun Choi; Kyoung Soo Kim; Hyejung Lee; Dae-Hyun Hahm
Journal:  Inflamm Res       Date:  2010-12-16       Impact factor: 4.575

Review 2.  Biological aspects in controlling angiogenesis: current progress.

Authors:  Mohsen Akbarian; Luiz E Bertassoni; Lobat Tayebi
Journal:  Cell Mol Life Sci       Date:  2022-06-07       Impact factor: 9.207

3.  Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells.

Authors:  Jamie S Mader; Daniel Smyth; Jean Marshall; David W Hoskin
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

4.  Correlation of concentrations of selected trace elements with Gleason grade of prostate tissues.

Authors:  A Banas; W M Kwiatek; K Banas; M Gajda; B Pawlicki; T Cichocki
Journal:  J Biol Inorg Chem       Date:  2010-05-25       Impact factor: 3.358

5.  Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo.

Authors:  Klas Norrby; Arvid Nordenhem
Journal:  APMIS       Date:  2010-10-12       Impact factor: 3.205

6.  Rat mesentery angiogenesis assay.

Authors:  Klas C Norrby
Journal:  J Vis Exp       Date:  2011-06-18       Impact factor: 1.355

7.  Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis.

Authors:  Per Albertsson; Bo Lennernäs; Klas Norrby
Journal:  APMIS       Date:  2011-10-25       Impact factor: 3.205

Review 8.  In vivo models of angiogenesis.

Authors:  K Norrby
Journal:  J Cell Mol Med       Date:  2006 Jul-Sep       Impact factor: 5.310

Review 9.  Dietary proteins and angiogenesis.

Authors:  Miguel Ángel Medina; Ana R Quesada
Journal:  Nutrients       Date:  2014-01-17       Impact factor: 5.717

10.  Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification.

Authors:  Samuel E DePrimo; Lily M Wong; Deepak B Khatry; Susan L Nicholas; William C Manning; Beverly D Smolich; Anne-Marie O'Farrell; Julie M Cherrington
Journal:  BMC Cancer       Date:  2003-02-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.